| Recruiting | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Vir NCT07020533 | City of Hope Medical Center | Phase 1 |
| Not Yet Recruiting | Pacritinib With Aza for Upfront Myelodysplastic Syndrome NCT07387354 | Thomas Jefferson University | Phase 1 / Phase 2 |
| Not Yet Recruiting | Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera NCT06290765 | PharmaEssentia | Phase 4 |
| Recruiting | Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE) NCT07119970 | University Hospital, Bordeaux | N/A |
| Recruiting | P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk NCT06468033 | PharmaEssentia | Phase 3 |
| Recruiting | Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Vers NCT06815003 | City of Hope Medical Center | Phase 2 |
| Recruiting | Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care NCT05745285 | University of Miami | N/A |
| Withdrawn | Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for NCT06284460 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Evaluation of the Pathobiology of CALR-mutated MPN Cells NCT06480591 | Wake Forest University Health Sciences | — |
| Withdrawn | Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT NCT03939585 | Leland Metheny | Phase 1 |
| Not Yet Recruiting | Prevalence and Risk Factors of Pulmonary Hypertension in Patients with Myeloproliferative Neoplasms in Assiut NCT06647706 | Assiut University | — |
| Suspended | Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia NCT06421155 | Case Comprehensive Cancer Center | N/A |
| Active Not Recruiting | Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of M NCT06553638 | University Hospital, Brest | — |
| Recruiting | Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hig NCT06013423 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Pat NCT06059391 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Diagnostic Characterization and Evolution of "Triple Negative" Thrombocytosis (CASTETTE) NCT06481332 | University Hospital, Brest | — |
| Recruiting | BeFluBu vs FluBuRux Conditioning in Haploidentical HCT NCT06477549 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Active Not Recruiting | Observatory of Patients With MyeloProliferative Neoplasm Treated With Anti-inflammatory Immunotherapy NCT06476535 | University Hospital, Brest | — |
| Recruiting | Exploring the Impact of Monocytes in Myeloproliferative Neoplasia (EMYNEM) NCT06462664 | University Hospital, Brest | — |
| Recruiting | Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes NCT06361641 | University Hospital, Angers | N/A |
| Recruiting | Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen NCT06532084 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Not Yet Recruiting | A Prospective Patient Reported Outcomes and Wearables Study in Myeloproliferative Neoplasms NCT06334913 | Guy's and St Thomas' NHS Foundation Trust | — |
| Withdrawn | Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms NCT04629651 | Case Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Unknown | A New Blood Score for Myelofibrosis Staging NCT06177366 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation NCT06138587 | Dana-Farber Cancer Institute | Phase 1 |
| Active Not Recruiting | Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagno NCT06034470 | Fred Hutchinson Cancer Center | Phase 1 |
| Recruiting | Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epige NCT06022328 | University Hospital, Bordeaux | — |
| Active Not Recruiting | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantati NCT06001385 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Recruiting | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution NCT06131801 | Children's Hospital Medical Center, Cincinnati | — |
| Recruiting | Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms NCT05074355 | University Health Network, Toronto | Phase 2 |
| Not Yet Recruiting | MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New NCT06022341 | University Hospital, Angers | N/A |
| Active Not Recruiting | Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodys NCT05600894 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Com NCT05839717 | University Hospital, Bordeaux | — |
| Recruiting | Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thr NCT05440838 | University Hospital, Angers | — |
| Recruiting | Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | Asian Myeloproliferative Neoplasm (MPN) Registry NCT05882773 | The University of Hong Kong | — |
| Recruiting | Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characte NCT06715267 | University Hospital, Brest | — |
| Recruiting | Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms NCT05850273 | Institut National de la Santé Et de la Recherche Médicale, France | — |
| Recruiting | Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms NCT05732961 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Unknown | Evaluation of Optical Genome Mapping in Phi Negative Myeloproliferative Neoplasia in the Detection of Acquired NCT05714592 | Centre Hospitalier Universitaire, Amiens | N/A |
| Unknown | Carotid Plaque Burden in Patients With Philadelphia Negative Myeloproliferative Neoplasms NCT05993052 | Sohag University | — |
| Active Not Recruiting | Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patien NCT05364762 | City of Hope Medical Center | Phase 2 |
| Completed | Role of Monocytes Sub-populations in Thrombosis Associated With Myeloproliferative Neoplasms (MonSThr) NCT05419648 | University Hospital, Bordeaux | — |
| Recruiting | Olverembatinib for FGFR1-rearranged Neoplasms NCT05521204 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Active Not Recruiting | Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin NCT04802161 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms NCT05455294 | Jacqueline Garcia, MD | Phase 1 |
| Terminated | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies NCT05107856 | Prelude Therapeutics | Phase 1 |
| Completed | PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation NCT05120570 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Terminated | Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms NCT05127174 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Active Not Recruiting | Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) NCT05177211 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Active Not Recruiting | Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms NCT04902833 | Massachusetts General Hospital | — |
| Terminated | Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast NCT05524857 | Joseph Jurcic | Phase 1 |
| Recruiting | An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms NCT05123365 | University of California, Irvine | Phase 1 / Phase 2 |
| Recruiting | Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant NCT04898790 | University of Nebraska | N/A |
| Withdrawn | A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neopla NCT04955938 | University of Chicago | Phase 1 |
| Recruiting | Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syn NCT04942080 | University Hospital, Angers | N/A |
| Completed | Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study NCT05053100 | Mayo Clinic | — |
| Completed | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candid NCT05972577 | Ohio State University Comprehensive Cancer Center | N/A |
| Withdrawn | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis Af NCT03602898 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neop NCT04279847 | Incyte Corporation | Phase 1 |
| Completed | Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT NCT04629430 | University of Virginia | N/A |
| Completed | Remotely Administered Diet Intervention to Impact Symptom Burden in Myeloproliferative Neoplasm NCT04744974 | University of California, Irvine | Phase 2 |
| Completed | Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies NCT04943757 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Completed | Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation NCT04942730 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Recruiting | CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic S NCT04493164 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neop NCT04637009 | Astex Pharmaceuticals, Inc. | Phase 1 |
| Not Yet Recruiting | Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo- NCT04451200 | Institut Paoli-Calmettes | Phase 2 |
| Completed | Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced M NCT04146038 | Rutgers, The State University of New Jersey | Phase 2 |
| Unknown | Anticoagulation in Gastroesophageal Varices and JAK2 Mutation NCT04527666 | Shanghai Zhongshan Hospital | — |
| Unknown | Gastroesophageal Varices in Cavernoma NCT04525768 | Shanghai Zhongshan Hospital | — |
| Completed | 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II NCT03941769 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | SARS-CoV-2 Donor-Recipient Immunity Transfer NCT04666025 | City of Hope Medical Center | — |
| Completed | A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors NCT04605211 | University of California, San Francisco | N/A |
| Unknown | Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm NCT04312607 | Safaa AA Khaled | — |
| Recruiting | Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferativ NCT04493138 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY). NCT04378855 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Completed | COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias NCT04416438 | French Innovative Leukemia Organisation | — |
| Completed | Myeloproliferative Neoplasms (MPN) and COVID-19 NCT04385160 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | — |
| Recruiting | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloprolif NCT04282187 | University of Washington | Phase 2 |
| Completed | Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms NCT04177576 | University Hospital, Bordeaux | — |
| Withdrawn | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem C NCT03807063 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy NCT04014764 | Notable Labs | — |
| Completed | Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies NCT04191187 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Active Not Recruiting | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation NCT04060277 | City of Hope Medical Center | Phase 2 |
| Terminated | Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MP NCT04103645 | Weill Medical College of Cornell University | Phase 2 |
| Recruiting | Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukem NCT03970096 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination NCT04041050 | AbbVie | Phase 1 |
| Completed | PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome NCT04022785 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms NCT04192916 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | — |
| Completed | MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis NCT04994158 | Royal Free Hospital NHS Foundation Trust | — |
| Recruiting | A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation NCT04024761 | Dana-Farber Cancer Institute | Phase 1 |
| Recruiting | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Bloo NCT03779854 | Fred Hutchinson Cancer Center | Phase 2 |
| Unknown | Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results NCT04060485 | National Taiwan University Hospital | — |
| Active Not Recruiting | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant NCT03622788 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT03862157 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myelop NCT03878199 | Ohio State University Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Bloo NCT03438344 | City of Hope Medical Center | Phase 2 |
| Recruiting | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndr NCT03630991 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood NCT03589729 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine NCT03588078 | Groupe Francophone des Myelodysplasies | Phase 1 / Phase 2 |
| Recruiting | Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malig NCT03471260 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid NCT03397173 | Case Comprehensive Cancer Center | Phase 2 |
| Unknown | CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies NCT03795779 | iCell Gene Therapeutics | EARLY_Phase 1 |
| Unknown | CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies NCT04156256 | iCell Gene Therapeutics | EARLY_Phase 1 |
| Active Not Recruiting | Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN NCT03386513 | AbbVie | Phase 1 / Phase 2 |
| Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry NCT03452774 | Massive Bio, Inc. | — |
| Terminated | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Pa NCT03333486 | Roswell Park Cancer Institute | Phase 2 |
| Completed | PREVALENCE STUDY OF PNH CLONES IN PATIENTS WITH NEOPLASIES NCT06159816 | AUSL Romagna Rimini | — |
| Unknown | Cardiac Changes in Myeloproliferative Neoplasms NCT03177928 | Assiut University | N/A |
| Active Not Recruiting | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus H NCT03192397 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase I NCT03238248 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Completed | The Feasibility of Delivering Consumer-based Meditation Applications to Myeloproliferative Neoplasm Patients NCT03726944 | Arizona State University | N/A |
| Withdrawn | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferati NCT02564536 | Washington University School of Medicine | Phase 1 |
| Completed | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in P NCT03128359 | City of Hope Medical Center | Phase 2 |
| Completed | Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms NCT03072043 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Completed | Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms NCT06371573 | Federico II University | — |
| Completed | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT02960646 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, NCT02728050 | University of Washington | Phase 1 / Phase 2 |
| Terminated | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Pa NCT02877082 | Emory University | Phase 2 |
| Completed | Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplan NCT02639559 | Washington University School of Medicine | Phase 2 |
| Active Not Recruiting | Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in NCT02521493 | Children's Oncology Group | Phase 3 |
| Completed | Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients Wi NCT02566304 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Active Not Recruiting | Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV a NCT02506933 | City of Hope Medical Center | Phase 2 |
| Recruiting | Project: Every Child for Younger Patients With Cancer NCT02402244 | Children's Oncology Group | — |
| Completed | CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Tr NCT02424968 | Robert Lowsky | Phase 2 |
| Completed | Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies NCT02396134 | City of Hope Medical Center | Phase 2 |
| Completed | Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation NCT02311569 | Swiss Cancer Institute | Phase 2 |
| Unknown | Outcomes in Patients With Myeloproliferative Neoplasm and Splanchnic Vein Thrombosis NCT04631458 | Royal Free Hospital NHS Foundation Trust | — |
| Completed | Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention NCT01951885 | Case Comprehensive Cancer Center | Phase 3 |
| Completed | Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk My NCT02121418 | University of Washington | N/A |
| Completed | Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia o NCT02029950 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Tran NCT01822509 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecu NCT05825326 | Sociedad de Lucha Contra el Cáncer del Ecuador | — |
| Completed | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated NCT01231412 | Fred Hutchinson Cancer Center | Phase 3 |
| Completed | Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of MNP Ph1- NCT02862366 | Lille Catholic University | — |
| Completed | Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off- NCT01362985 | Genzyme, a Sanofi Company | — |
| Completed | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer NCT00723099 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treati NCT00397813 | Fred Hutchinson Cancer Center | Phase 2 |